Navigation Links
Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
Date:11/6/2009

DURHAM, N.C., Nov. 6 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that a previously approved reverse split of its common stock will take effect at the start of trading on Monday, Nov. 9, 2009 on a 1-for-15 split-adjusted basis. Oxygen Biotherapeutics, Inc. shares will trade under the new symbol OXBT. The stock also will have a new CUSIP number, 69207P 20 9, when the split becomes effective.

"This reverse split was overwhelmingly approved by our shareholders in support of our plan to move the listing of our shares to a major exchange from the over-the-counter bulletin board," said Chris Stern, company chairman and CEO. "We believe that moving the listing will enhance the liquidity of our shares and improve our ability to attract new investors as we move ahead with our product development plans. We have filed the application to move our listing and will be working to facilitate and execute the listing move as fast as the stock exchange will allow us to do it. I'll have some additional comments on this in a blog posting on our company website later today."

The 1-for-15 reverse stock split will automatically convert 15 current shares of Oxygen Biotherapeutics, Inc. common stock into one new share of common stock. If the number of shares is not evenly divisible by the ratio of the reverse split, the shareholder's new share count will be rounded up to the nearest whole share. The reverse split, which was approved by shareholders on October 19, 2009, will reduce the number of outstanding shares of common stock from 293,985,804 to approximately 19,599,676.

Furthermore, the number of shares of common stock subject to outstanding stock options, warrants, or convertible securities, and the exercise prices and conversion ratios of those securities, will automatically be proportionately adjusted for the 1 to 15 ratio provided for by the reverse stock split. The number of authorized shares will not change.

When the reverse split takes effect, stockholders holding shares in "street name" through a brokerage account will have their shares automatically adjusted to reflect the reverse stock split on the effective date. The issuance of new stock certificates will not be required at this time.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. referring to plans to move the listing of the company's shares to a major exchange that involve risks and uncertainties and reflect the company's judgment as of the date of this release. There can be no assurance that those plans and expectations will be realized. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE Oxygen Biotherapeutics, Inc.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
2. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
3. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
4. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
5. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
6. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
7. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
8. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
9. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
10. McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP
11. Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... , ... Maury Regional Health has announced a large-scale adoption of AccuVein vein ... Maury Regional Medical Center is making vein visualization part of their standard of care. ... more importantly, helps our staff members locate a vein that will provide good access ...
(Date:8/16/2017)... ... August 16, 2017 , ... With a new PD ... ultimately, a cure. , The grants are awarded through a competitive application process ... a wide array of backgrounds and expertise in all areas relevant to PD research. ...
(Date:8/16/2017)... Sacramento, CA (PRWEB) , ... August 16, 2017 ... ... ($10.99, paperback, 9781498499613; $5.99, eBook, 9781498499620    ) shares that during the time of a ... as reminding Strawn of God's love, and all the many ways God shows ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... ... pain afflicting 8 of 10 Americans at some point in their lives, some of us ... equally vexing condition stems from a variety of causes that can be effectively targeted by ... president of Atlantic Spine Center. , Nestled between your neck and lower back, the ...
Breaking Medicine News(10 mins):